Diabetes mellitus (D.M.) is a major medical problem throughout the world. The prevalence of diabetes in India is 2.4% in the rural population and 4.0-11.6% in the urban population. It is estimated that 20% of the current global diabetic population resides in the Southeast Asia region. Worldwide 150 million cases are currently diagnosed, predicted to be doubled by 2025. India is committed to an initiative of Vision 2020: The Right to Sight, thus having targets for ophthalmic infrastructure in its tenth five-year plan. Diabetes mellitus (D.M.) is a significant cause of avoidable blindness in both developing and developed countries. Patients with diabetic retinopathy (DR) are 25 times more likely to become blind than non-diabetics. In the natural course, approximately 50% of patients with very severe N.P.D.R. (non-proliferative diabetic retinopathy) progress to PDR (proliferative diabetic retinopathy) within 1 year. Panretinal photocoagulation (P.R.P.) is the preferred form of treatment for proliferative diabetic retinopathy (P.D.R.). The DRS found that PRP (pan retinal photocoagulation) prevented severe visual loss by over 50% at 2 and 4 years of followup. However, many studies have been done on pan-retinal photocoagulation for proliferative diabetic retinopathy. The aim of this study is to observe the clinical profile, visual outcome and quality of life in patients undergoing pan-retinal photocoagulation for proliferative diabetic retinopathy.